Pharmacokinetics, Pharmacodynamics and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Cov...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Pharmacol Ther
मुख्य लेखकों: Kim, Hanna, Brooks, Kristina M., Tang, Cheng Cai, Wakim, Paul, Blake, Mary, Brooks, Stephen R., Sanchez, Gina A. Montealegre, de Jesus, Adriana A., Huang, Yan, Tsai, Wanxia Li, Gadina, Massimo, Prakash, Apurva, Janes, Jonathan Marcus, Zhang, Xin, Macias, William L., Kumar, Parag, Goldbach-Mansky, Raphaela
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089664/
https://ncbi.nlm.nih.gov/pubmed/29134648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.936
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन